Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BROMOCRIPTINE MESYLATE vs HYRNUO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
(E)-2-(((2-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)thio)methyl)-4-methyl-2H-pyrazolo[1,5-a]pyrazin-3(5H)-one is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4. It binds to the ATP-binding site of FGFR kinases, blocking downstream signaling pathways, including RAS-MAPK-ERK and PI3K-AKT, thereby inhibiting tumor cell proliferation and angiogenesis.
FDA-approved: Treatment of hyperprolactinemia (including amenorrhea/galactorrhea, hypogonadism, infertility) associated with prolactin-secreting adenomas,FDA-approved: Adjunctive treatment of Parkinson disease (idiopathic or postencephalitic),FDA-approved: Treatment of acromegaly (as an adjunct to surgery or radiotherapy),Off-label: Type 2 diabetes mellitus (improves glycemic control),Off-label: Neuroleptic malignant syndrome,Off-label: Prevention of postpartum lactation (use not recommended due to serious adverse events)
Treatment of adult patients with previously treated, unresectable locally advanced or metastatic urothelial carcinoma (UC) with FGFR3 genetic alterations,Treatment of adult patients with unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 gene fusions or other rearrangements
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
100 mg orally once daily
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
Terminal elimination half-life is 12-15 hours in adults with normal renal function, supporting twice-daily dosing.
Extensively metabolized primarily by cytochrome P450 3A4 (CYP3A4) to multiple metabolites, including the major active metabolite 2-bromo-α-ergocriptine. Also undergoes non-CYP-mediated hydrolysis and conjugation. First-pass metabolism is significant, resulting in ~6% oral bioavailability.
Primarily metabolized by CYP2C9 and CYP3A4; minor contributions from CYP2C19 and CYP2D6. Forms active metabolites M1 (desmethyl) and M2 (N-oxide).
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30% (including metabolites), with the remainder eliminated via minor metabolic pathways.
90-96% bound to serum albumin, with some binding to alpha-1-acid glycoprotein.
98% bound primarily to albumin.
Approximately 2-3 L/kg, indicating extensive tissue distribution and penetration into breast milk and central nervous system.
0.3-0.4 L/kg, indicating distribution into total body water with limited tissue binding.
Oral: 28-30% due to extensive first-pass metabolism; sublingual: 40-50% due to partial avoidance of hepatic first-pass; rectal: approximately 20%.
Oral: 85% (fasting); 60% with high-fat meal (reduced absorption).
No specific dose adjustment recommended; monitor for accumulation in severe renal impairment (e GFR <30 m L/min).
GFR ≥60 m L/min: No adjustment. GFR 30-59: 50 mg once daily. GFR <30: Not recommended.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
Prolactinomas: 1.25-2.5 mg/m²/day orally in 2-3 divided doses; titrate based on response. Weight-based: 0.01-0.02 mg/kg/day, increase slowly.
Not established for patients under 18 years.
Initiate at low end of dosing range (1.25 mg once or twice daily) due to increased sensitivity and risk of hypotension; titrate slowly.
No specific dose adjustment; monitor renal function and consider age-related decline.
None
None
May cause hypotension (especially postural), syncope, and severe adverse reactions such as myocardial infarction, stroke, seizures, and psychosis. Can cause pleural and retroperitoneal fibrosis, pericarditis, and valvulopathy (especially with high doses for Parkinson disease). Has been associated with pathological gambling, hypersexuality, and impulse control disorders. May cause somnolence and sudden sleep onset. Monitor for cardiac valvulopathy and pulmonary fibrosis. Use with caution in patients with cardiovascular disease, peptic ulcer disease, or a history of mental illness.
Retinal pigment epithelial detachment (RPED) and other visual disturbances: conduct ophthalmic examinations prior to and during treatment,Hyperphosphatemia: monitor serum phosphate levels and manage with phosphate-lowering therapy or dose modification,Non-healing corneal ulcers: requires ophthalmologic evaluation,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception
Absolute: Hypersensitivity to bromocriptine or ergot alkaloids; uncontrolled hypertension; pregnancy (toxemia of pregnancy); preeclampsia/eclampsia; coronary artery disease or other significant cardiovascular disease; severe renal or hepatic impairment. Relative: History of peptic ulcer disease, psychiatric disorders, Raynaud phenomenon, or hepatic impairment.
Concurrent use with strong CYP2C9 or CYP3A4 inducers,Pregnancy and lactation
Take with food to reduce gastrointestinal irritation; avoid high-protein meals if using for hyperprolactinemia as protein may decrease absorption.
No specific food interactions. Grapefruit juice does not significantly affect HYRNUO metabolism. Maintain consistent vitamin K intake if on warfarin; not applicable to HYRNUO. Alcohol may increase bleeding risk; advise moderation.
First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage due to uterine atony; may suppress pituitary prolactin, potentially impairing placental lactogen production. Overall, use only if clearly needed.
HYRNUO is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies and limited human data. First trimester exposure is associated with major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios.
Bromocriptine suppresses lactation by inhibiting prolactin secretion. It is contraindicated in breastfeeding women due to the intended suppression of milk production. No M/P ratio available; minimal excretion into breast milk is expected but not well studied.
No data available on excretion into breast milk or effects on the breastfed infant. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.
No specific dose adjustments are recommended for pregnancy; however, the drug is generally discontinued once pregnancy is confirmed unless necessary for prolactinoma treatment. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may theoretically alter levels, but data are insufficient to recommend dose changes.
No established safe dose in pregnancy. Drug should not be used. If accidental exposure occurs, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose adjustment, but no specific recommendations exist.
Titrate slowly to minimize orthostatic hypotension and gastrointestinal upset. Administer with food to reduce nausea. Monitor for pulmonary fibrosis and Raynaud phenomenon with long-term use. Avoid concomitant use with ergot alkaloids due to additive vasospasm risk.
HYRNUO is a novel oral anticoagulant with high specificity for factor Xa. Monitor renal function prior to initiation and periodically; adjust dose if Cr Cl <30 m L/min. No routine coagulation monitoring required. Reversal agent andexanet alfa is available for life-threatening bleeding. Avoid in patients with mechanical heart valves or moderate-to-severe mitral stenosis. Caution with dual antiplatelet therapy due to increased bleeding risk.
Take with food to reduce nausea and lightheadedness.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol as it may worsen side effects.,Report persistent cough, chest pain, or changes in urination or vision.,Do not stop abruptly; taper under medical supervision.
Take HYRNUO exactly as prescribed, usually once daily with or without food.,Do not skip doses; if a dose is missed, take it as soon as remembered on the same day. Do not double the next dose.,Inform all healthcare providers that you are taking HYRNUO, especially before surgery or dental procedures.,Watch for signs of bleeding: unusual bruising, prolonged bleeding from cuts, pink/brown urine, red/black stools, coughing up blood, or vomiting blood.,Avoid aspirin, NSAIDs, or other blood thinners unless prescribed by your doctor.,Keep a list of all medications and supplements you take, as some may interact with HYRNUO.,Store at room temperature away from moisture and heat. Do not stop taking without consulting your doctor.
"Coadministration of bromocriptine, a dopamine D2 receptor agonist with vasoconstrictive properties, and ergometrine, an ergot alkaloid that acts as a partial agonist at alpha-adrenergic and serotonin receptors, synergistically increases peripheral vasoconstriction. This additive effect can lead to severe hypertension, myocardial ischemia, cerebral vasospasm, and potentially life-threatening ergotism. Patients may present with headache, chest pain, altered mental status, or peripheral ischemia."
"Concurrent use of bromocriptine, a dopamine D2 receptor agonist, and enasidenib, an IDH2 inhibitor, may lead to increased risk of central nervous system adverse effects, including dizziness, somnolence, and extrapyramidal symptoms. Enasidenib inhibits CYP3A4, which metabolizes bromocriptine, potentially elevating bromocriptine plasma concentrations. This pharmacokinetic interaction can exacerbate dopaminergic toxicity, especially in patients with hepatic impairment or those on high-dose bromocriptine."
"Bromocriptine, a dopamine D2 receptor agonist and ergot derivative, is primarily metabolized by CYP3A4. Astemizole, a second-generation antihistamine, is also metabolized by CYP3A4. Concomitant use of these two drugs can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of both agents. Elevated bromocriptine levels raise the risk of ergotism (vasospasm, ischemia) and neuropsychiatric toxicities, while increased astemizole concentrations may prolong the QT interval, predisposing patients to life-threatening ventricular arrhythmias such as torsades de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BROMOCRIPTINE MESYLATE vs HYRNUO, answered by our medical review team.
BROMOCRIPTINE MESYLATE is a Dopamine Agonist that works by Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.. HYRNUO is a Dopamine Agonist (Antiparkinsonian) that works by (E)-2-(((2-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)thio)methyl)-4-methyl-2H-pyrazolo[1,5-a]pyrazin-3(5H)-one is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4. It binds to the ATP-binding site of FGFR kinases, blocking downstream signaling pathways, including RAS-MAPK-ERK and PI3K-AKT, thereby inhibiting tumor cell proliferation and angiogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BROMOCRIPTINE MESYLATE and HYRNUO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BROMOCRIPTINE MESYLATE is: Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).. The standard adult dose of HYRNUO is: 100 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BROMOCRIPTINE MESYLATE and HYRNUO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BROMOCRIPTINE MESYLATE is classified as Category A/B. First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage. HYRNUO is classified as Category C. HYRNUO is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies and limited human data. First trimester exposure is associated with major congenital mal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.